Kobayashi Pharmaceutical stock (JP3301100008): Red yeast rice crisis continues to impact shares

Kobayashi Pharmaceutical, the Japanese consumer health firm behind the toxic red yeast rice supplement, continues to grapple with the aftermath of a major safety scandal. In March 2024, the company recalled products after reports of kidney failures and at least five deaths linked to the ingredient puberulic acid. Shares plunged over 40% in the ensuing weeks, according to Reuters as of 04/05/2024. The crisis prompted government investigations and lawsuits, with impacts lingering into 2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Kobayashi Pharmaceutical: core business model

Kobayashi Pharmaceutical develops and sells over-the-counter drugs, quasi-drugs, and health supplements primarily in Japan. Founded in 1854, the company focuses on innovative products addressing everyday health concerns like foot odor, digestive issues, and cold remedies. Its flagship brands include 'Kobayashi' branded items sold through drugstores and supermarkets. Revenue for fiscal 2023, published March 2024, reached 183.8 billion JPY, up 6.7% year-over-year per the company IR site as of 03/28/2024.

The business model emphasizes research-driven product development, with over 1,000 items in its portfolio. Kobayashi invests heavily in marketing quirky, problem-solving ads that resonate in Japan. For US investors, the firm's exposure to Asia's aging population offers indirect play on regional healthcare trends, though listed solely on the Tokyo Stock Exchange.

Main revenue and product drivers for Kobayashi Pharmaceutical

Key products include Blistex-like balms, eye drops, and supplements. Pre-scandal, red yeast rice tablets were a bestseller for cholesterol management. Post-recall, the company shifted focus to core OTC drugs, which accounted for 70% of sales in FY2023. Stomach medicines and skin care drove growth, per annual report data published March 2024.

Distribution relies on Japan's dense pharmacy network. Exports to Asia contribute modestly. The scandal disrupted supply chains, leading to a 2024 sales drop estimated at 20-30% by analysts, though Q3 FY2025 results showed stabilization, according to Nikkei Asia as of 02/10/2025.

Industry trends and competitive position

Japan's OTC market grows at 3-5% annually, driven by self-medication trends amid rising healthcare costs, per Statista data published 2025. Kobayashi holds about 5% market share, competing with Rohto and Taisho. Its innovation edge—such as patented odor-control tech—sets it apart, but the scandal eroded consumer trust.

Competitors like Eisai benefit from pharma diversification. Kobayashi's pure-play consumer focus amplifies scandal risks but offers high margins (operating 12% in FY2023).

Why Kobayashi Pharmaceutical matters for US investors

Listed on TSE, Kobayashi provides US investors exposure to Japan's stable consumer staples via ADRs or direct trading. With $4 trillion US ETF inflows into international equities in 2025, per Bloomberg, firms like this offer diversification from US tech. The scandal creates a potential value play if recovery materializes.

The red yeast rice scandal: timeline and impacts

The crisis erupted March 22, 2024, when Kobayashi halted sales of red yeast rice products after 1,000+ health complaints. Puberulic acid contamination caused acute kidney injury. By April 2024, five deaths confirmed, per Bloomberg as of 04/10/2024. Shares hit eight-year lows below 3,000 JPY.

2025 updates include class-action suits and MHLW fines. Recovery efforts involve new safety protocols and R&D pivot, with shares trading around 4,500 JPY as of May 2026 on TSE, per exchange data.

Risks and open questions

Ongoing litigation and reputational damage pose downside risks. Regulatory scrutiny may cap growth. Positive: Strong balance sheet with net cash supports buybacks, announced FY2025.

Conclusion

Kobayashi Pharmaceutical's shares remain pressured by the 2024 scandal, with recovery dependent on trust rebuilding and regulatory clearance. Financials show resilience in core segments, but litigation lingers. US investors eyeing Japan consumer plays should monitor Q1 FY2026 earnings for progress signals. The firm retains innovation strengths amid sector tailwinds.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.